Exagen Inc.

Executive Summary

BUY, Medium conviction. XGN rates a BUY, Medium conviction at $7.45. The company has shifted from a turnaround story to evidence of operating leverage, with Q2 revenue at a record $19.9M and adjusted EBITDA loss narrowed to $0.1M. The setup is not clean after a 69% three-month move, but the stock remains 39.1% below its 52-week high and the raised FY26 outlook provides a fundamental path beyond a momentum trade.

Investment Thesis

At $7.45, XGN offers a small-cap diagnostics turnaround with visible evidence that its commercial model is improving. The market capitalization is only $0.2B, while the business is producing better unit economics from a focused autoimmune-testing franchise. This is not a claim that profitability has arrived. It is a claim that the gap between the current loss profile and breakeven is narrowing faster than the legacy financials suggest.

The first dependency is sustained demand in the core franchise. AVISE CTD has produced 13 consecutive quarters of ASP growth, and the company is pairing higher reimbursement realization with increased clinician use. This matters because the model has fixed laboratory and commercial costs. If pricing and test volume continue to rise together, incremental gross profit should improve meaningfully without requiring a major sales-force build.

The second dependency is revenue mix. Pharma-services backlog is now over $6M, which can add profitable work and diversify XGN from clinical reimbursement. It is also inherently uneven, so it should not be valued as recurring clinical-test revenue. The third is execution on Myositis. Management plans an early-2027 launch using its existing sales force and CPT billing, a capital-efficient approach. A delayed launch would not break the existing AVISE case, but it would weaken the next leg of growth.

Valuation is reasonable on sales rather than earnings: XGN trades at 2.53x TTM sales, below the stated 3.6x peer average, although peer comparisons are weak because all five named peers have N/A P/E and are not clean operating analogues. The stock is still 51.0% above its 200-day average, so buyers should expect volatility and should not mistake the recent pullback for a washed-out setup. Medium conviction reflects that a small company with unresolved reimbursement timing, negative earnings, and uneven quarterly cash flow can disappoint quickly. The reward is attractive only if management proves that the recent operating leverage is repeatable.

Key Metrics

Financial Strength

Liquidity is adequate for the near term, supported by a 3.18x current ratio and nearly $25M of cash, equivalents, and restricted cash at the end of Q2. Leverage nevertheless matters because debt-to-equity exceeds 2x and the company has not established durable free-cash-flow generation. Margin direction is favorable, with the LTM operating loss materially narrower than the FY2025 loss, but the balance sheet should be viewed as funding a path to breakeven rather than as insulating the company from a multi-quarter setback.

Competitive Position

XGN's protection comes from rheumatology clinician adoption, established AVISE CTD ordering and billing workflows, and a growing longitudinal dataset around autoimmune testing. The current 40-territory sales footprint gives the company a focused commercial channel, while the existing sales force can support the Myositis launch without a disclosed expansion. Durability is moderate rather than high: payer coverage and physician trust take time to earn, but larger diagnostic laboratories can compete on contracting, distribution, and menu breadth.

Management & Guidance

Management raised FY26 revenue guidance after first-half results outperformed internal plans and expects high-single-digit AVISE CTD volume growth, mid-single-digit ASP growth versus the Q4 2025 exit rate, and a gross-margin exit rate of at least 60%. Guidance quality is better than it was in 2024 because it is supported by current volume, pricing, and collections data, but management has appropriately warned that normal fewer-business-day and vacation effects will pressure the second half. The company’s stated long-term adjusted EBITDA breakeven threshold of around $80M in annual revenue remains a useful marker, not a FY26 promise.

Segment Analysis

• AVISE CTD clinical testing (Not disclosed): Core clinical franchise; volume reached nearly 39,000 tests in Q2 2026, up 11% YoY.
• Pharma services (More than $1M of Q2 2026 revenue): Higher-margin but potentially lumpy business, with contract backlog above $6M.
• Geography (Not disclosed): The company does not disclose geographic revenue in the supplied materials.

Capital Allocation

Capital allocation is appropriately defensive for a company still below sustained profitability. Deep-dive data reports $0.0B of buybacks, dividends, and capex, while LTM free cash flow was reported at $-0.0B, indicating management is preserving resources rather than returning capital. The stronger use of cash is working capital discipline and targeted development, including revenue-cycle automation and a Myositis launch planned through the existing commercial organization.

Management Execution & Track Record

Management has materially advanced the operating model from the 2024 Q2 call, when it guided FY24 revenue of at least $57M, an adjusted EBITDA loss better than $12M, AVISE CTD marker upgrades by year-end, and cash-flow positivity within one year of both marker launches. Current FY26 guidance is $72M-$75M, versus the earlier $57M floor, and Q2 2026 revenue of $19.9M compares with $15.1M in Q2 2024. AVISE trailing-12-month ASP improved from above $400 in 2024 Q2 to $446 currently, showing that the pricing strategy has progressed. The supplied data do not provide FY24 actual revenue, EBITDA, or post-launch cash flow, so the original FY24 promises cannot be scored as formally met or missed. Credibility is nevertheless improving: seven of the last eight reported quarters met or beat EPS expectations, including beats of 29.2% and 32.1% in May and August 2026, with the notable exception a 46.2% miss in November 2025.

Positioning & Flows

Ownership is relatively concentrated but not institutionally crowded: the top three institutions own 25.1% and insiders own 16.5%. Short interest is modest at 4.89%, or 704,634 shares, and fell 12%; with only 2.2 days-to-cover against a 14M-share float, the data do not support a major short-squeeze thesis. Options gamma is negative within 45 days to expiry, which can amplify downside around earnings, while usable zero-gamma and call-wall levels were not supplied.

Bull Case

• FY26 revenue guidance of $72M-$75M implies management sees first-half outperformance carrying through known second-half seasonality.
• Gross margin was just over 61% in Q2 2026, up about 90 bps YoY, giving incremental revenue unusually strong conversion potential for a diagnostics company of this size.
• Pharma-services revenue exceeded $1M in Q2 and contract backlog surpassed $6M after growing about $1M, creating a second revenue source beyond clinical testing.
• Q2 cash generation was $3.1M, aided by more than $1M of collections from claims older than 360 days and H1 collections exceeding the prior year by $9M.

Bear Case

• LTM operating margin was still -18.6% through June 30, 2026, and management explicitly does not expect near-breakeven adjusted EBITDA to persist in the second half.
• Debt-to-equity was 2.09x as of June 30, 2026 and LTM free cash flow was reported at $-0.0B, leaving limited room for sustained execution misses.
• Medicare LCD timing remains unresolved after the MolDX request has been pending since 2022, which can delay reimbursement clarity and clinical adoption.
• The shares trade at 14.74x TTM P/B despite FY2025 net margin of -27.3%, so a renewed cash burn cycle could pressure the equity sharply.

Valuation & Price Target

Engine price target $8.21 (+10.3% vs current), High confidence.

• P/S Multiple: $8.71 (45% weight)
• Quality-adjusted: $7.09 (20% weight)

The quantitative engine's HOLD and $8.21 target imply only 10.3% upside, so this is not a high-conviction valuation call. The BUY rating deliberately leans on trajectory: FY2025 revenue grew only 0.1% YoY, but the latest quarter grew 16% and management raised the FY26 midpoint by $2M while reaching a $0.1M adjusted EBITDA loss. That improving sales quality warrants accepting modest target upside, though the 44/100 quality score and 54/100 Moderate risk score keep conviction at Medium. Sell-side Strong Buy consensus from four firms is low-signal context and does not drive the rating.

Risk Assessment

Risk score 54/100 (Moderate). The central risk is that H2 seasonality and spending reverse Q2 progress, leaving an LTM operating margin of -18.6% without a credible route to the roughly $80M annual-revenue EBITDA-breakeven threshold.

The Bottom Line

XGN is a BUY for investors able to tolerate small-cap diagnostics volatility. The key fact is not the still-negative earnings base, but the combination of record revenue, better pricing, rising gross margin, and a narrowed EBITDA loss. The November 3 report must show that those gains survive normal second-half seasonality. A break below the FY26 revenue range, a material deterioration in collections, or a delayed Myositis launch would change the view to HOLD or SELL because the company’s leverage leaves little cushion.